gemfibrozil has been researched along with Aging in 6 studies
Aging: The gradual irreversible changes in structure and function of an organism that occur as a result of the passage of time.
| Excerpt | Relevance | Reference |
|---|---|---|
| "Gemfibrozil (GFZ) is a medication of the fibrate category with agonistic effects on peroxisome proliferator-activated receptor-α (PPAR-α) and is effective for hypertriglyceridemia and mixed dyslipidemia." | 5.91 | Gemfibrozil, a lipid-lowering drug, improves hepatorenal damages in a mouse model of aging. ( Fatemi, I; Giménez-Llort, L; Hakimizadeh, E; Hassanipour, M; Soltani, A; Tadayon, S; Zamanian, MY, 2023) |
| "Gemfibrozil (GFZ) is a lipid-lowering drug with several other effects, such as antioxidant and anti-inflammatory activities." | 5.72 | Gemfibrozil, a lipid-lowering drug, reduces anxiety, enhances memory, and improves brain oxidative stress in d-galactose-induced aging mice. ( Borisov, VV; Ehsani, V; Fatemi, I; Giménez-Llort, L; Hakimizadeh, E; Hassanshahi, J; Kaeidi, A; Khajehasani, F; Movahedinia, S; Zamanian, MY, 2022) |
| "Gemfibrozil (GFZ) is a medication of the fibrate category with agonistic effects on peroxisome proliferator-activated receptor-α (PPAR-α) and is effective for hypertriglyceridemia and mixed dyslipidemia." | 1.91 | Gemfibrozil, a lipid-lowering drug, improves hepatorenal damages in a mouse model of aging. ( Fatemi, I; Giménez-Llort, L; Hakimizadeh, E; Hassanipour, M; Soltani, A; Tadayon, S; Zamanian, MY, 2023) |
| "Gemfibrozil (GFZ) is a lipid-lowering drug with several other effects, such as antioxidant and anti-inflammatory activities." | 1.72 | Gemfibrozil, a lipid-lowering drug, reduces anxiety, enhances memory, and improves brain oxidative stress in d-galactose-induced aging mice. ( Borisov, VV; Ehsani, V; Fatemi, I; Giménez-Llort, L; Hakimizadeh, E; Hassanshahi, J; Kaeidi, A; Khajehasani, F; Movahedinia, S; Zamanian, MY, 2022) |
| "We previously verified a physiologically based pharmacokinetic (PBPK) model for mirabegron in healthy subjects using the Simcyp Simulator by incorporating data on the inhibitory effect on cytochrome P450 (CYP) 2D6 and a multi-elimination pathway mediated by CYP3A4, uridine 5'-diphosphate-glucuronosyltransferase (UGT) 2B7 and butyrylcholinesterase (BChE)." | 1.51 | Application of a physiologically based pharmacokinetic model for the prediction of mirabegron plasma concentrations in a population with severe renal impairment. ( Konishi, K; Minematsu, T; Nagasaka, Y; Tabata, K, 2019) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 3 (50.00) | 29.6817 |
| 2010's | 1 (16.67) | 24.3611 |
| 2020's | 2 (33.33) | 2.80 |
| Authors | Studies |
|---|---|
| Hakimizadeh, E | 2 |
| Zamanian, MY | 2 |
| Borisov, VV | 1 |
| Giménez-Llort, L | 2 |
| Ehsani, V | 1 |
| Kaeidi, A | 1 |
| Hassanshahi, J | 1 |
| Khajehasani, F | 1 |
| Movahedinia, S | 1 |
| Fatemi, I | 2 |
| Tadayon, S | 1 |
| Soltani, A | 1 |
| Hassanipour, M | 1 |
| Konishi, K | 1 |
| Minematsu, T | 1 |
| Nagasaka, Y | 1 |
| Tabata, K | 1 |
| Sanguino, E | 3 |
| Ramón, M | 1 |
| Michalik, L | 1 |
| Wahli, W | 1 |
| Alegret, M | 3 |
| Sánchez, RM | 3 |
| Vázquez-Carrera, M | 3 |
| Laguna, JC | 3 |
| Roglans, N | 2 |
6 other studies available for gemfibrozil and Aging
| Article | Year |
|---|---|
Gemfibrozil, a lipid-lowering drug, reduces anxiety, enhances memory, and improves brain oxidative stress in d-galactose-induced aging mice.
Topics: Aging; Animals; Antioxidants; Anxiety; Brain; Eosine Yellowish-(YS); Galactose; Gemfibrozil; Hematox | 2022 |
Gemfibrozil, a lipid-lowering drug, improves hepatorenal damages in a mouse model of aging.
Topics: Aging; Animals; Antioxidants; Disease Models, Animal; Gemfibrozil; Hypolipidemic Agents; Liver; Male | 2023 |
Application of a physiologically based pharmacokinetic model for the prediction of mirabegron plasma concentrations in a population with severe renal impairment.
Topics: Acetanilides; Adolescent; Adrenergic beta-3 Receptor Agonists; Adult; Aged; Aging; Butyrylcholineste | 2019 |
Lack of hypotriglyceridemic effect of gemfibrozil as a consequence of age-related changes in rat liver PPARalpha.
Topics: Acyl-CoA Oxidase; Aging; Animals; CCAAT-Enhancer-Binding Proteins; DNA-Binding Proteins; Gemfibrozil | 2004 |
Prevention of age-related changes in rat cortex transcription factor activator protein-1 by hypolipidemic drugs.
Topics: Aging; Animals; Cerebral Cortex; Cyclooxygenase 2; Female; Gemfibrozil; Gene Expression; Hypolipidem | 2004 |
Different response of senescent female Sprague-Dawley rats to gemfibrozil and rosiglitazone administration.
Topics: Adipose Tissue; Aging; Animals; Blood Glucose; Body Weight; Cholesterol; Diet; DNA-Binding Proteins; | 2005 |